Viewing Study NCT03674203


Ignite Creation Date: 2025-12-24 @ 7:35 PM
Ignite Modification Date: 2025-12-29 @ 11:09 AM
Study NCT ID: NCT03674203
Status: COMPLETED
Last Update Posted: 2019-01-28
First Post: 2018-09-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy of Platelet-rich Plasma in Treatment of Melasma
Sponsor: Instituto Mexicano del Seguro Social
Organization:

Study Overview

Official Title: Efficacy of Platelet-rich Plasma in Treatment of Melasma
Status: COMPLETED
Status Verified Date: 2019-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The application of Platelet Rich Plasma (PRP) on three occasions with an interval of 15 days between each one, is related to a decrease in the intensity of the spots and improvement in the quality of the skin of patients with melasma.
Detailed Description: 832/5000 Objective: To evaluate the effect of PRP for Melasma treatment. Material and methods: Prospective cohort with therapeutic intervention. Patients, female, with melasma were included. Changes in the melanin concentration of the face (MASI), degree of satisfaction (MELASQOL) and histological changes were clinically evaluated.

The Sp-MELASQOL questionnaire, Fitzpatrick and MASI scales were applied, and photographs were taken with ambient light and with Wood's light with the Janus-II General Model. The patients were evaluated and classified, before and after the treatment by means of dermatoscopy, which was performed using a dermatoscope with polarized light (DermLite DL3N®), which allows an increase from 6 to 400X.

The dermatoscopy reported the findings of: Quantity, Density and Depth of melasma.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: